104 related articles for article (PubMed ID: 23328452)
1. New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia.
Mattison RJ; Luger SM; Lazarus HM
Curr Opin Hematol; 2013 Mar; 20(2):93-9. PubMed ID: 23328452
[TBL] [Abstract][Full Text] [Related]
2. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
Wongprajun S; Auewarakul CU
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
[TBL] [Abstract][Full Text] [Related]
3. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
4. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
6. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?
Ofran Y
Curr Opin Hematol; 2016 Mar; 23(2):108-14. PubMed ID: 26717195
[TBL] [Abstract][Full Text] [Related]
7. The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.
Grosicki S; Holowiecki J; Giebel S; Kyrcz-Krzemien S; Kuliczkowski K; Kielbinski M; Skotnicki AB; Piatkowska-Jakubas B; Hellmann A; Wierzbowska A; Stella-Holowiecka B; Zdziarska B; Calbecka M
Am J Hematol; 2011 May; 86(5):437-9. PubMed ID: 21465518
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of early treatment response in children with acute myeloid leukemia].
Tie LJ; Gu LJ; Song DL; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J; Wang YP; Zou JY
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(26):1837-40. PubMed ID: 17054861
[TBL] [Abstract][Full Text] [Related]
9. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
[TBL] [Abstract][Full Text] [Related]
10. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
Al-Mawali A; Gillis D; Lewis I
Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
[TBL] [Abstract][Full Text] [Related]
11. Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
Vial JP; Tabrizi R; Pigneux A; Lacombe F; Praloran V; Belloc F
Cytometry B Clin Cytom; 2006 May; 70(3):115-23. PubMed ID: 16572429
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of plasmacytosis in the day+14 bone marrow of patients with acute myeloid leukaemia undergoing induction chemotherapy.
Al-Shughair N; Al-Dawsari G; Gyger M; Mohamed G; Roberts G
J Clin Pathol; 2007 May; 60(5):520-3. PubMed ID: 16731597
[TBL] [Abstract][Full Text] [Related]
13. CD34 immunohistochemistry in bone marrow biopsies for early response assessment in acute myeloid leukemia.
Jain S; Mahapatra M; Pati HP
Int J Lab Hematol; 2015 Dec; 37(6):746-51. PubMed ID: 26248894
[TBL] [Abstract][Full Text] [Related]
14. New methods for assessing response in acute myeloid leukemia.
Hall AC; Mattison RJ
Curr Opin Hematol; 2015 Mar; 22(2):132-8. PubMed ID: 25584823
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
Pullarkat V; Aldoss I
Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
[TBL] [Abstract][Full Text] [Related]
17. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
20. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
